Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.60 |
| ▸ | SRC | P12931 | 9/20 | 0.60 |
| ▸ | ABL1 | P00519 | 7/20 | 0.60 |
| ▸ | ABL2 | P42684 | 6/20 | 0.60 |
| ▸ | RET | P07949 | 9/20 | 0.59 |
| ▸ | LCK | P06239 | 3/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | MST1R | Q04912 | 2/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122419 | 0.97 | RET (0.61) | EGFRSRCABL1ABL2RET | |
| SCHEMBL27620914 | 0.83 | EGFR (0.66) | EGFRSRCABL1ABL2RET | |
| SCHEMBL5116426 | 0.81 | RET (0.45) | EGFRSRCABL1ABL2RET | |
| SCHEMBL1941336 | 0.80 | EGFR (0.66) | EGFRSRCABL1ABL2RET | |
| SCHEMBL1940945 | 0.79 | RET (0.59) | EGFRSRCABL1ABL2RET | |
| SCHEMBL29926654 | 0.79 | SRC (0.66) | EGFRSRCABL1ABL2RET | |
| SCHEMBL28627629 | 0.79 | SRC (0.66) | EGFRSRCABL1ABL2RET | |
| SCHEMBL28627632 | 0.79 | SRC (0.66) | EGFRSRCABL1ABL2RET | |
| SCHEMBL19732709 | 0.78 | RET (0.63) | EGFRSRCABL1ABL2RET | |
| SCHEMBL19264162 | 0.77 | SRC (0.61) | EGFRSRCABL1ABL2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| CN-108026101-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-3269370-A1 | NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | EGFR 1502/4885SRC 456/4885ABL1 158/4885 |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | EGFR 1502/4885SRC 456/4885ABL1 158/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | EGFR 1243/4885SRC 259/4885ABL1 84/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | EGFR 607/4885SRC 235/4885ABL1 187/4885 |
| US-10179788-B2 | — | RET, GFRA1, GFRA2 | EGFR 590/4885SRC 146/4885ABL1 164/4885 |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | EGFR 1243/4885SRC 259/4885ABL1 84/4885 |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | EGFR 1243/4885SRC 259/4885ABL1 84/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | EGFR 590/4885SRC 146/4885ABL1 164/4885 |
| US-20200270261-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | EGFR 1176/4885SRC 153/4885ABL1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.